Drug profile · INN
omacetaxine mepesuccinate
TEKINEX
omacetaxine mepesuccinate (TEKINEX) is a protein synthesis inhibitor. Associated with Teva Pharma GmbH. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — omacetaxine mepesuccinate
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 10
- Data quality
- 0.89
Quick answer
omacetaxine mepesuccinate (TEKINEX) is a protein synthesis inhibitor. Associated with Teva Pharma GmbH. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Protein synthesis inhibitor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | application withdrawn | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is omacetaxine mepesuccinate?
omacetaxine mepesuccinate (TEKINEX) is a protein synthesis inhibitor. Associated with Teva Pharma GmbH. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for omacetaxine mepesuccinate?
TEKINEX is a marketed brand name for omacetaxine mepesuccinate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of omacetaxine mepesuccinate?
omacetaxine mepesuccinate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.